Citius shareholders elect directors, approve 2023 equity plan, ratify auditor

Next, at the meeting, our stockholders approved the Citius Pharmaceuticals, Inc. 2023 Omnibus Stock Incentive Plan. The vote for such approval was 22,065,354 shares for, 6,944,243 shares against, 780,696 shares abstaining, and 45,937,200 broker non-votes.

Finally, at the meeting, our stockholders ratified the selection of Wolf & Company, P.C. as our independent registered public accounting firm for the fiscal year ending September 30, 2023. The vote for such approval was 73,110,304 shares for, 1,546,136 shares against, 1,071,053 shares abstaining, and no broker non-votes.

We held our 2023 annual meeting of stockholders on February 7, 2023. At the meeting, stockholders elected the following seven members to our Board of Directors for a one-year term expiring at the annual meeting of stockholders to be held in 2024 and until their successors are duly elected and qualified, based on the following votes: Nominee For Withheld Broker Non-Votes Myron Holubiak 27,833,866 1,956,427 45,937,200 Leonard Mazur 27,708,003 2,082,290 45,937,200 Suren Dutia 27,404,373 2,385,920 45,937,200 Carol Webb 27,206,268 2,584,025 45,937,200 Howard Safir 27,493,869 2,296,424 45,937,200 Dr. Eugene Holuka 27,093,439 2,696,854 45,937,200 Dennis M. McGrath 27,486,435 2,303,858 45,937,200